Lower Alzheimer’s risk seen with PDE5i initiation for erectile dysfunction
Feb 08, 2024
The greatest reduction in risk was seen for those receiving 21 to 50 phosphodiesterase type 5 inhibitor prescriptions.
Certain genetic variant in Alzheimer’s disease linked to African ancestry
Feb 22, 2023
An increased risk for Alzheimer’s disease and younger age of onset were seen with the APOE ε3 R145C missense variation.
Prevalence of LATE-NC explored in seniors, Alzheimer’s disease
Jun 20, 2022
Almost 40% of those with Alzheimer’s disease neuropathologic change had a limbic-predominant age-related TDP-43 encephalopathy neuropathologic change.
New Alzheimer’s disease drug delivers disappointing results
Jun 17, 2022
The trial was the first to test a drug meant to delay or halt mental decline in people who have a genetic predisposition.
Levetiracetam well-tolerated for Alzheimer’s disease
Oct 01, 2021
It does not improve primary outcome but did improve performance on certain cognitive tasks in those with epileptiform activity.
FDA head asks for investigation into Alzheimer’s disease drug approval
Jul 12, 2021
The request follows reports that Biogen and the FDA held off-the-books meetings before the drug’s approval that may have violated FDA protocol.
Prediction model for brain age may help detect cognitive decline
Jul 01, 2021
Greater differences between predicted age based on brain MRI and actual age were seen in those with amnestic mild cognitive impairment versus healthy controls.
Lilly to seek FDA approval for new drug for Alzheimer’s disease
Jun 25, 2021
Donanemab already has received a ‘breakthrough therapy’ designation from the FDA.
ARIA described from clinical trials of aducanumab for Alzheimer’s disease
Dec 10, 2021
Amyloid-related imaging abnormalities-edema seen on brain MRI was the most common adverse event in participants receiving high-dose aducanumab (Aduhelm).
Vestibular system impairment tied to fall risk in Alzheimer’s patients
Mar 18, 2022
A significant association was seen between semicircular canal function with lower likelihood of falls in adjusted analysis.